Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41,009,592
-
Total 13F shares
-
2,294,684
-
Share change
-
+24,343
-
Total reported value
-
$5,987,665
-
Put/Call ratio
-
47%
-
Price per share
-
$2.61
-
Number of holders
-
54
-
Value change
-
-$130,637
-
Number of buys
-
25
-
Number of sells
-
19
Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q3 2023
As of 30 Sep 2023,
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,294,684 shares.
The largest 10 holders included
BML Capital Management, LLC, Rathbones Group PLC, TWO SIGMA ADVISERS, LP, GOLDMAN SACHS GROUP INC, GSA CAPITAL PARTNERS LLP, BlackRock Inc., MORGAN STANLEY, STATE STREET CORP, Squarepoint Ops LLC, and JPMORGAN CHASE & CO.
This page lists
54
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.